TCGX launches $600 million Asia-focused biotech fund to back life-science companies in China and the region
TCGX, a biotech investment firm led by Chen Yu and Dandan Dong, announced a new $600 million fund aimed at the Asian market.
The fund will make direct investments in life-science companies located in China and other Asian countries, giving TCGX a more hands‑on role in the region's biotech ecosystem.
Based in Palo Alto, California, TCGX operates both private and public investment vehicles and is expanding its geographic focus beyond the United States.
The launch underscores growing investor interest in Asian biotech pipelines and could provide much‑needed capital to emerging companies in the area.
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “TCGX doubles down on China with $600M Asia-focused fund”
read at Endpoints ↗
comments(0)
5-min edit window · permanent after that